AdvaMed® Statement on President Biden’s National Address Tonight
WASHINGTON, D.C. – AdvaMed®, the world’s largest trade organization representing medical technology companies, released the following statement from President and CEO Scott Whitaker:
COVID-19
O2TODAY and SINTX Technologies Enter Commercialization Agreement to Fight COVID-19
O2TODAY (“O2TODAY”), a mask company that develops, manufactures and commercializes face masks for medical and non-medical uses, and SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”) (www.sintx.com), an original…
AdvaMed® Statement on Administration’s Expanded Investment in COVID Testing
WASHINGTON, D.C. – The Advanced Medical Technology Association® (AdvaMed®)—the world’s largest trade association for medical technology and diagnostics companies in the world—released the following statement from President and CEO Scott Whitaker on…
AdvaMed® Re-Launches Web-Based Platform to Assist Government with Potential Supply Shortfalls
AdvaMed® unveiled a newly repurposed platform to help device manufacturers locate and partner with thousands of component part manufacturers and sellers, should they need them during the COVID pandemic.
AdvaMed® Statement on EU Export Restrictions of COVID-19 Vaccines
AdvaMed® President and CEO Scott Whitaker released a statement on the announcement by the European Union that COVID-19 vaccines covered by an Advanced Purchase Agreement (APA) require in many instances…
AdvaMed® Letter to President Biden on Defense Production Act: Ready to Continue Industry Efforts to Defeat COVID-19
WASHINGTON, D.C. – Today AdvaMed® President and CEO Scott Whitaker sent a letter to President Biden affirming the industry’s support of the administration’s national COVID-19 strategy and sharing the industry’s perspective on…
AdvaMed® Statement on Participation in HHS Vaccine Consultation Panel
WASHINGTON, D.C. – Today AdvaMed® President and CEO Scott Whitaker released the following statement about AdvaMed®’s participation on the HHS Vaccine Consultation Panel.
Ortho’s VITROS® SARS-CoV-2 Antigen Test for Accurate, Mass-Scale COVID-19 Testing is the First Widely-Available, High-Volume Test to Receive FDA Emergency Use Authorization
Ortho’s VITROS® SARS-CoV-2 Antigen Test is the first high-volume COVID-19 antigen test to receive Food and Drug Administration (FDA) Emergency Use Authorization (EUA).
Guided By Principles-Based Management in Times of Crisis & Uncertainty
Unequal access to medical technologies and, more broadly, health care services continues to persist – often disproportionately impacting the lives of racial and ethnic minorities.
AdvaMed® Statement on HHS Rescission of Policies on Laboratory Developed Tests During COVID and Beyond
WASHINGTON, D.C. – AdvaMed® President and CEO Scott Whitaker released the following statement: